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We thank Professor Cohen for his reply and his interesting points regarding the possible role of 
inadequate folinic acid rescue in contributing to neurotoxic side-effects of methotrexate. We can 
confirm that the patient reported in our article1 had not received any previous exposure to any 
systemic methotrexate (oral or intravenous) even at low dose. In addition, the other published 
article on this possible interaction with nitrous oxide2 reported a patient developing symptoms early 
during induction therapy on a protocol with a standard 3-drug induction (vincristine, asparaginase 
and corticosteroids). Therefore concomitant systemic methotrexate appears not to be a contributing 
factor in either of these reported cases.  
As pointed out by Prof Cohen the recent article by Krull et al3 indicates, for the first time in acute 
lymphoblastic leukaemia (ALL), a direct association between methotrexate plasma levels (area under 
the curve) and adverse long-term neurocognitive outcomes.  The role of folinic acid rescue in 
prevention of neurotoxic side effects remains speculative4,5  and has never been tested in a 
randomised trial. In addition, the impact of over-rescue on leukaemic relapse is still uncertain6,7 and 
differences in scheduling and concomitant chemotherapy as well as individual pharmacogenomics 
are all likely to play a part. 
It is worth noting that nitrous oxide irreversibly inactivates vitamin B12 – a co-factor for methionine 
synthase- rather than directly interfering with Methotrexate induced inhibition of dihydrofolate 
reductase8. Since methionine synthase activity is required for homocysteine to methionine 
conversion,  it may be that, in the presence of low/inactive B12, the efficacy of folinic acid rescue in 
reducing neurotoxic symptoms related to high homocysteine9 and/or low methionine is more 
limited.  In other words, even in the presence of adequate folinic acid rescue, the conversion of 
homocysteine to methionine may still be impaired due to low methionine synthase activity. 
However, to our knowledge this has never been tested experimentally.' 
In summary, further studies are clearly needed to investigate the optimal dosing of both 
methotrexate and folinic acid rescue in order to balance efficacy and toxicity. Yet, we still believe 
that the most effective way of reducing this potential drug interaction is to limit exposure to nitrous 
oxide, especially as a number of safe non-toxic alternative anaesthetic agents are in routine use.   
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